Potential Drugs in COVID-19 Management
- Authors: Gasmi A.1, Noor S.2, Menzel A.3, Khanyk N.4, Semenova Y.5, Lysiuk R.4, Beley N.6, Bolibrukh L.7, Gasmi Benahmed A.8, Storchylo O.9, Bjørklund G.10
-
Affiliations:
- , Société Francophone de Nutrithérapie et de Nutrigénétique Appliquée
- Institute of Molecular Biology and Biotechnology, Bahauddin Zakariya University
- , Laboratoires Réunis
- , Danylo Halytsky Lviv National Medical University
- School of Medicine, Nazarbayev University
- , I. Ya. Horbachevsky Ternopil National Medical University
- , Lviv Polytechnic National University
- , Académie Internationale de Médecine Dentaire Intégrative
- Medical Chemistry Department,, Odessa National Medical University
- , Council for Nutritional and Environmental Medicine (CONEM)
- Issue: Vol 31, No 22 (2024)
- Pages: 3245-3264
- Section: Anti-Infectives and Infectious Diseases
- URL: https://rjpbr.com/0929-8673/article/view/644757
- DOI: https://doi.org/10.2174/0929867331666230717154101
- ID: 644757
Cite item
Full Text
Abstract
The SARS-CoV-2 virus first emerged in China in December 2019 and quickly spread worldwide. Despite the absence of a vaccination or authorized drug specifically developed to combat this infection, certain medications recommended for other diseases have shown potential effectiveness in treating COVID-19, although without definitive confirmation. This review aims to evaluate the existing literature on the efficacy of these medications against COVID-19. The review encompasses various potential treatments, including antiviral medications, anti-malaria and anti-rheumatic drugs, vaccines, corticosteroids, non-steroidal anti-inflammatory drugs (NSAIDs), antipyretic and analgesic medicines, antiparasitic drugs, and statins. The analysis also addresses the potential benefits and drawbacks of these medications, as well as their effects on hypertension and diabetes. Although these therapies hold promise against COVID-19, further research, including suitable product production or clinical testing, is needed to establish their therapeutic efficacy.
Keywords
About the authors
Amin Gasmi
, Société Francophone de Nutrithérapie et de Nutrigénétique Appliquée
Email: info@benthamscience.net
Sadaf Noor
Institute of Molecular Biology and Biotechnology, Bahauddin Zakariya University
Email: info@benthamscience.net
Alain Menzel
, Laboratoires Réunis
Email: info@benthamscience.net
Nataliia Khanyk
, Danylo Halytsky Lviv National Medical University
Email: info@benthamscience.net
Yuliya Semenova
School of Medicine, Nazarbayev University
Email: info@benthamscience.net
Roman Lysiuk
, Danylo Halytsky Lviv National Medical University
Email: info@benthamscience.net
Nataliya Beley
, I. Ya. Horbachevsky Ternopil National Medical University
Email: info@benthamscience.net
Liliia Bolibrukh
, Lviv Polytechnic National University
Email: info@benthamscience.net
Asma Gasmi Benahmed
, Académie Internationale de Médecine Dentaire Intégrative
Email: info@benthamscience.net
Olha Storchylo
Medical Chemistry Department,, Odessa National Medical University
Email: info@benthamscience.net
Geir Bjørklund
, Council for Nutritional and Environmental Medicine (CONEM)
Author for correspondence.
Email: info@benthamscience.net
References
- Zhou, F.; Yu, T.; Du, R.; Fan, G.; Liu, Y.; Liu, Z.; Xiang, J.; Wang, Y.; Song, B.; Gu, X.; Guan, L.; Wei, Y.; Li, H.; Wu, X.; Xu, J.; Tu, S.; Zhang, Y.; Chen, H.; Cao, B. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study. Lancet, 2020, 395(10229), 1054-1062. doi: 10.1016/S0140-6736(20)30566-3 PMID: 32171076
- Wu, Z.; McGoogan, J.M. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: Summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA, 2020, 323(13), 1239-1242. doi: 10.1001/jama.2020.2648 PMID: 32091533
- Mahase, E. Long covid could be four different syndromes, review suggests. BMJ, 2020, 371, m3981. doi: 10.1136/bmj.m3981 PMID: 33055076
- Liu, J.; Liu, Y.; Xiang, P.; Pu, L.; Xiong, H.; Li, C.; Zhang, M.; Tan, J.; Xu, Y.; Song, R. Neutrophil-to-lymphocyte ratio predicts severe illness patients with 2019 novel coronavirus in the early stage. J. Transl. Med., 2020, 18(1), 206. doi: 10.1186/s12967-020-02374-0 PMID: 32434518
- Cao, Q.; Chen, Y.C.; Chen, C.L.; Chiu, C.H. SARS-CoV-2 infection in children: Transmission dynamics and clinical characteristics. J. Formos. Med. Assoc., 2020, 119(3), 670-673. doi: 10.1016/j.jfma.2020.02.009 PMID: 32139299
- Peiris, J.S.M.; Chu, C.M.; Cheng, V.C.C.; Chan, K.S.; Hung, I.F.N.; Poon, L.L.M.; Law, K.I.; Tang, B.S.F.; Hon, T.Y.W.; Chan, C.S.; Chan, K.H.; Ng, J.S.C.; Zheng, B.J.; Ng, W.L.; Lai, R.W.M.; Guan, Y.; Yuen, K.Y. Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: A prospective study. Lancet, 2003, 361(9371), 1767-1772. doi: 10.1016/S0140-6736(03)13412-5 PMID: 12781535
- Chen, N.; Zhou, M.; Dong, X.; Qu, J.; Gong, F.; Han, Y.; Qiu, Y.; Wang, J.; Liu, Y.; Wei, Y.; Xia, J.; Yu, T.; Zhang, X.; Zhang, L. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study. Lancet, 2020, 395(10223), 507-513. doi: 10.1016/S0140-6736(20)30211-7 PMID: 32007143
- Huang, W.H.; Teng, L.C.; Yeh, T.K.; Chen, Y.J.; Lo, W.J.; Wu, M.J.; Chin, C.S.; Tsan, Y.T.; Lin, T.C.; Chai, J.W.; Lin, C.F.; Tseng, C.H.; Liu, C.W.; Wu, C.M.; Chen, P.Y.; Shi, Z.Y.; Liu, P.Y. 2019 novel coronavirus disease (COVID-19) in Taiwan: Reports of two cases from Wuhan, China. J. Microbiol. Immunol. Infect., 2020, 53(3), 481-484. doi: 10.1016/j.jmii.2020.02.009 PMID: 32111449
- Lee, P.I.; Hu, Y.L.; Chen, P.Y.; Huang, Y.C.; Hsueh, P.R. Are children less susceptible to COVID-19? J. Microbiol. Immunol. Infect., 2020, 53(3), 371-372. doi: 10.1016/j.jmii.2020.02.011 PMID: 32147409
- Zamorano Cuervo, N.; Grandvaux, N. ACE2: Evidence of role as entry receptor for SARS-CoV-2 and implications in comorbidities. eLife, 2020, 9, e61390. doi: 10.7554/eLife.61390 PMID: 33164751
- Ni, W.; Yang, X.; Yang, D.; Bao, J.; Li, R.; Xiao, Y.; Hou, C.; Wang, H.; Liu, J.; Yang, D.; Xu, Y.; Cao, Z.; Gao, Z. Role of angiotensin-converting enzyme 2 (ACE2) in COVID-19. Crit. Care, 2020, 24(1), 422. doi: 10.1186/s13054-020-03120-0 PMID: 32660650
- Hofmann, H.; Pyrc, K.; van der Hoek, L.; Geier, M.; Berkhout, B.; Pöhlmann, S. Human coronavirus NL63 employs the severe acute respiratory syndrome coronavirus receptor for cellular entry. Proc. Natl. Acad. Sci., 2005, 102(22), 7988-7993. doi: 10.1073/pnas.0409465102 PMID: 15897467
- Lee, K.H.; Yoo, S.G.; Cho, Y.; Kwon, D.E.; La, Y.; Han, S.H.; Kim, M.S.; Choi, J.S.; Kim, S.I.; Kim, Y.S.; Min, Y.H.; Cheong, J.W.; Kim, J.S.; Song, Y.G. Characteristics of community-acquired respiratory viruses infections except seasonal influenza in transplant recipients and non-transplant critically ill patients. J. Microbiol. Immunol. Infect., 2021, 54(2), 253-260. doi: 10.1016/j.jmii.2019.05.007 PMID: 31262511
- Lee, P.I.; Hsueh, P.R. Emerging threats from zoonotic coronaviruses-from SARS and MERS to 2019-nCoV. J. Microbiol. Immunol. Infect., 2020, 53(3), 365-367. doi: 10.1016/j.jmii.2020.02.001 PMID: 32035811
- To, K.K.W.; Tsang, O.T.Y.; Leung, W.S.; Tam, A.R.; Wu, T.C.; Lung, D.C.; Yip, C.C.Y.; Cai, J.P.; Chan, J.M.C.; Chik, T.S.H.; Lau, D.P.L.; Choi, C.Y.C.; Chen, L.L.; Chan, W.M.; Chan, K.H.; Ip, J.D.; Ng, A.C.K.; Poon, R.W.S.; Luo, C.T.; Cheng, V.C.C.; Chan, J.F.W.; Hung, I.F.N.; Chen, Z.; Chen, H.; Yuen, K.Y. Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: An observational cohort study. Lancet Infect. Dis., 2020, 20(5), 565-574. doi: 10.1016/S1473-3099(20)30196-1 PMID: 32213337
- Peeri, N.C.; Shrestha, N.; Rahman, M.S.; Zaki, R.; Tan, Z.; Bibi, S.; Baghbanzadeh, M.; Aghamohammadi, N.; Zhang, W.; Haque, U. The SARS, MERS and novel coronavirus (COVID-19) epidemics, the newest and biggest global health threats: What lessons have we learned? Int. J. Epidemiol., 2020, 49(3), 717-726. doi: 10.1093/ije/dyaa033 PMID: 32086938
- Semenova, Y.; Trenina, V.; Pivina, L.; Glushkova, N.; Zhunussov, Y.; Ospanov, E.; Bjørklund, G. The lessons of COVID-19, SARS, and MERS: Implications for preventive strategies. Int. J. Healthc. Manag., 2022, 15(4), 314-324. doi: 10.1080/20479700.2022.2051126
- Lui, G.; Guaraldi, G. Drug treatment of COVID-19 infection. Curr. Opin. Pulm. Med., 2023, 29(3), 174-183. doi: 10.1097/MCP.0000000000000953 PMID: 36917228
- Yuan, Y.; Jiao, B.; Qu, L.; Yang, D.; Liu, R. The development of COVID-19 treatment. Front. Immunol., 2023, 14, 1125246. doi: 10.3389/fimmu.2023.1125246 PMID: 36776881
- Chu, C.M.; Cheng, V.C.; Hung, I.F.; Wong, M.M.; Chan, K.H.; Chan, K.S.; Kao, R.Y.; Poon, L.L.; Wong, C.L.; Guan, Y.; Peiris, J.S.; Yuen, K.Y. Role of lopinavir/ritonavir in the treatment of SARS: Initial virological and clinical findings. Thorax, 2004, 59(3), 252-256. doi: 10.1136/thorax.2003.012658 PMID: 14985565
- Cao, B.; Wang, Y.; Wen, D.; Liu, W.; Wang, J.; Fan, G.; Ruan, L.; Song, B.; Cai, Y.; Wei, M.; Li, X.; Xia, J.; Chen, N.; Xiang, J.; Yu, T.; Bai, T.; Xie, X.; Zhang, L.; Li, C.; Yuan, Y.; Chen, H.; Li, H.; Huang, H.; Tu, S.; Gong, F.; Liu, Y.; Wei, Y.; Dong, C.; Zhou, F.; Gu, X.; Xu, J.; Liu, Z.; Zhang, Y.; Li, H.; Shang, L.; Wang, K.; Li, K.; Zhou, X.; Dong, X.; Qu, Z.; Lu, S.; Hu, X.; Ruan, S.; Luo, S.; Wu, J.; Peng, L.; Cheng, F.; Pan, L.; Zou, J.; Jia, C.; Wang, J.; Liu, X.; Wang, S.; Wu, X.; Ge, Q.; He, J.; Zhan, H.; Qiu, F.; Guo, L.; Huang, C.; Jaki, T.; Hayden, F.G.; Horby, P.W.; Zhang, D.; Wang, C. A trial of lopinavirritonavir in adults hospitalized with severe Covid-19. N. Engl. J. Med., 2020, 382(19), 1787-1799. doi: 10.1056/NEJMoa2001282 PMID: 32187464
- Lim, J.; Jeon, S.; Shin, H-Y.; Kim, M.J.; Seong, Y.M.; Lee, W.J.; Choe, K-W.; Kang, Y.M.; Lee, B.; Park, S-J. Case of the index patient who caused tertiary transmission of COVID-19 infection in Korea: the application of lopinavir/ritonavir for the treatment of COVID-19 infected pneumonia monitored by quantitative RT-PCR. J. Korean Med. Sci., 2020, 35(6), e79. doi: 10.3346/jkms.2020.35.e79 PMID: 32056407
- Kim, U.J.; Won, E.J.; Kee, S.J.; Jung, S.I.; Jang, H.C. Combination therapy with lopinavir/ritonavir, ribavirin and interferon-α for Middle East respiratory syndrome. Antivir. Ther., 2016, 21(5), 455-459. doi: 10.3851/IMP3002 PMID: 26492219
- Rosa, S.G.V.; Santos, W.C. Clinical trials on drug repositioning for COVID-19 treatment. Rev. Panam. Salud Publica, 2020, 44, 1. doi: 10.26633/RPSP.2020.40 PMID: 32256547
- Dong, L.; Hu, S.; Gao, J. Discovering drugs to treat coronavirus disease 2019 (COVID-19). Drug Discov. Ther., 2020, 14(1), 58-60. doi: 10.5582/ddt.2020.01012 PMID: 32147628
- Cai, Q.; Yang, M.; Liu, D.; Chen, J.; Shu, D.; Xia, J.; Liao, X.; Gu, Y.; Cai, Q.; Yang, Y.; Shen, C.; Li, X.; Peng, L.; Huang, D.; Zhang, J.; Zhang, S.; Wang, F.; Liu, J.; Chen, L.; Chen, S.; Wang, Z.; Zhang, Z.; Cao, R.; Zhong, W.; Liu, Y.; Liu, L. Experimental treatment with favipiravir for COVID-19: An open-label control study. Engineering, 2020, 6(10), 1192-1198. doi: 10.1016/j.eng.2020.03.007 PMID: 32346491
- Cyranoski, D.; Abbott, A. Virus detectives seek source of SARS in Chinas wild animals. Nature, 2003, 423(6939), 467. doi: 10.1038/423467a PMID: 12774078
- Morgenstern, B.; Michaelis, M.; Baer, P.C.; Doerr, H.W.; Cinatl, J., Jr Ribavirin and interferon-β synergistically inhibit SARS-associated coronavirus replication in animal and human cell lines. Biochem. Biophys. Res. Commun., 2005, 326(4), 905-908. doi: 10.1016/j.bbrc.2004.11.128 PMID: 15607755
- Khalili, J.S.; Zhu, H.; Mak, N.S.A.; Yan, Y.; Zhu, Y. Novel coronavirus treatment with ribavirin: Groundwork for an evaluation concerning COVID-19. J. Med. Virol., 2020, 92(7), 740-746. doi: 10.1002/jmv.25798 PMID: 32227493
- Elfiky, A.A. Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study. Life Sci., 2020, 253, 117592. doi: 10.1016/j.lfs.2020.117592 PMID: 32222463
- Holshue, M.L.; DeBolt, C.; Lindquist, S.; Lofy, K.H.; Wiesman, J.; Bruce, H.; Spitters, C.; Ericson, K.; Wilkerson, S.; Tural, A.; Diaz, G.; Cohn, A.; Fox, L.; Patel, A.; Gerber, S.I.; Kim, L.; Tong, S.; Lu, X.; Lindstrom, S.; Pallansch, M.A.; Weldon, W.C.; Biggs, H.M.; Uyeki, T.M.; Pillai, S.K. First case of 2019 novel coronavirus in the United States. N. Engl. J. Med., 2020, 382(10), 929-936. doi: 10.1056/NEJMoa2001191 PMID: 32004427
- Agostini, M.L.; Andres, E.L.; Sims, A.C.; Graham, R.L.; Sheahan, T.P.; Lu, X.; Smith, E.C.; Case, J.B.; Feng, J.Y.; Jordan, R.; Ray, A.S.; Cihlar, T.; Siegel, D.; Mackman, R.L.; Clarke, M.O.; Baric, R.S.; Denison, M.R. Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease. MBio, 2018, 9(2), e00221-18. doi: 10.1128/mBio.00221-18 PMID: 29511076
- Lim, S.Y.; Guo, Z.; Liu, P.; McKay, L.G.A.; Storm, N.; Griffiths, A.; Qu, M.D.; Finberg, R.W.; Somasundaran, M.; Wang, J.P. Anti-SARS-CoV-2 activity of adamantanes in vitro and in animal models of infection. COVID, 2022, 2(11), 1551-1563. doi: 10.3390/covid2110111 PMID: 37274537
- deVries, T.; Dentiste, A.; Handiwala, L.; Jacobs, D. Bioavailability and pharmacokinetics of once-daily amantadine extended-release tablets in healthy volunteers: results from three randomized, crossover, open-label, phase 1 studies. Neurol. Ther., 2019, 8(2), 449-460. doi: 10.1007/s40120-019-0144-1 PMID: 31372936
- Zhou, Y.; Gammeltoft, K.A.; Galli, A.; Offersgaard, A.; Fahnøe, U.; Ramirez, S.; Bukh, J.; Gottwein, J.M. Efficacy of ion-channel inhibitors amantadine, memantine and rimantadine for the treatment of SARS-CoV-2 in vitro. Viruses, 2021, 13(10), 2082. doi: 10.3390/v13102082 PMID: 34696509
- Rejdak, K.; Fiedor, P.; Bonek, R.; Goch, A.; Gala-Błądzińska, A.; Chełstowski, W.; Łukasiak, J.; Kiciak, S.; Dąbrowski, P.; Dec, M.; Król, Z.J.; Papuć, E.; Zasybska, A.; Segiet, A.; Grieb, P. The use of amantadine in the prevention of progression and treatment of COVID-19 symptoms in patients infected with the SARS-CoV-2 virus (COV-PREVENT): Study rationale and design. Contemp. Clin. Trials, 2022, 116, 106755. doi: 10.1016/j.cct.2022.106755 PMID: 35390511
- Barczyk, A.; Czajkowska-Malinowska, M.; Farnik, M.; Barczyk, M.; Boda, Ł.; Cofta, S.; Duława, J.; Dyrbuś, M.; Harat, R.; Huk, M.; Kotecka, S.; Nahorecki, A.; Nasiłowski, J.; Naumnik, W.; Przybylski, G.; Słaboń-Willand, M.; Skoczyński, S.; Wita, K.; Zioło, G.; Kuna, P. Efficacy of oral amantadine among patients hospitalised with COVID-19: A randomised, double-blind, placebo-controlled, multicentre study. Respir. Med., 2023, 212, 107198. doi: 10.1016/j.rmed.2023.107198 PMID: 36931576
- Keyser, L.A.; Karl, M.; Nafziger, A.N.; Bertino, J.S., Jr Comparison of central nervous system adverse effects of amantadine and rimantadine used as sequential prophylaxis of influenza A in elderly nursing home patients. Arch. Intern. Med., 2000, 160(10), 1485-1488. doi: 10.1001/archinte.160.10.1485 PMID: 10826462
- Hayden, F.G.; Hoffman, H.E.; Spyker, D.A. Differences in side effects of amantadine hydrochloride and rimantadine hydrochloride relate to differences in pharmacokinetics. Antimicrob. Agents Chemother., 1983, 23(3), 458-464. doi: 10.1128/AAC.23.3.458 PMID: 6847173
- Touret, F.; de Lamballerie, X. Of chloroquine and COVID-19. Antiviral Res., 2020, 177, 104762. doi: 10.1016/j.antiviral.2020.104762 PMID: 32147496
- Wang, M.; Cao, R.; Zhang, L.; Yang, X.; Liu, J.; Xu, M.; Shi, Z.; Hu, Z.; Zhong, W.; Xiao, G. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res., 2020, 30(3), 269-271. doi: 10.1038/s41422-020-0282-0 PMID: 32020029
- Vincent, M.J.; Bergeron, E.; Benjannet, S.; Erickson, B.R.; Rollin, P.E.; Ksiazek, T.G.; Seidah, N.G.; Nichol, S.T. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol. J., 2005, 2(1), 69. doi: 10.1186/1743-422X-2-69 PMID: 16115318
- Boulware, D.R.; Pullen, M.F.; Bangdiwala, A.S.; Pastick, K.A.; Lofgren, S.M.; Okafor, E.C.; Skipper, C.P.; Nascene, A.A.; Nicol, M.R.; Abassi, M.; Engen, N.W.; Cheng, M.P.; LaBar, D.; Lother, S.A.; MacKenzie, L.J.; Drobot, G.; Marten, N.; Zarychanski, R.; Kelly, L.E.; Schwartz, I.S.; McDonald, E.G.; Rajasingham, R.; Lee, T.C.; Hullsiek, K.H. A randomized trial of hydroxychloroquine as postexposure prophylaxis for Covid-19. N. Engl. J. Med., 2020, 383(6), 517-525. doi: 10.1056/NEJMoa2016638 PMID: 32492293
- Bhimraj, A.; Morgan, R.L.; Shumaker, A.H.; Baden, L.; Cheng, V.C.C.; Edwards, K.M.; Gallagher, J.C.; Gandhi, R.T.; Muller, W.J.; Nakamura, M.M.; OHoro, J.C.; Shafer, R.W.; Shoham, S.; Murad, M.H.; Mustafa, R.A.; Sultan, S.; Falck-Ytter, Y. Infectious diseases society of America guidelines on the treatment and management of patients with COVID-19. Clin. Infect. Dis., 2022, ciac724. doi: 10.1093/cid/ciac724 PMID: 36063397
- Luo, P.; Liu, Y.; Qiu, L.; Liu, X.; Liu, D.; Li, J. Tocilizumab treatment in COVID-19: A single center experience. J. Med. Virol., 2020, 92(7), 814-818. doi: 10.1002/jmv.25801 PMID: 32253759
- Stone, J.H.; Frigault, M.J.; Serling-Boyd, N.J.; Fernandes, A.D.; Harvey, L.; Foulkes, A.S.; Horick, N.K.; Healy, B.C.; Shah, R.; Bensaci, A.M.; Woolley, A.E.; Nikiforow, S.; Lin, N.; Sagar, M.; Schrager, H.; Huckins, D.S.; Axelrod, M.; Pincus, M.D.; Fleisher, J.; Sacks, C.A.; Dougan, M.; North, C.M.; Halvorsen, Y.D.; Thurber, T.K.; Dagher, Z.; Scherer, A.; Wallwork, R.S.; Kim, A.Y.; Schoenfeld, S.; Sen, P.; Neilan, T.G.; Perugino, C.A.; Unizony, S.H.; Collier, D.S.; Matza, M.A.; Yinh, J.M.; Bowman, K.A.; Meyerowitz, E.; Zafar, A.; Drobni, Z.D.; Bolster, M.B.; Kohler, M.; DSilva, K.M.; Dau, J.; Lockwood, M.M.; Cubbison, C.; Weber, B.N.; Mansour, M.K. Efficacy of tocilizumab in patients hospitalized with Covid-19. N. Engl. J. Med., 2020, 383(24), 2333-2344. doi: 10.1056/NEJMoa2028836 PMID: 33085857
- Salvarani, C.; Dolci, G.; Massari, M.; Merlo, D.F.; Cavuto, S.; Savoldi, L.; Bruzzi, P.; Boni, F.; Braglia, L.; Turrà, C.; Ballerini, P.F.; Sciascia, R.; Zammarchi, L.; Para, O.; Scotton, P.G.; Inojosa, W.O.; Ravagnani, V.; Salerno, N.D.; Sainaghi, P.P.; Brignone, A.; Codeluppi, M.; Teopompi, E.; Milesi, M.; Bertomoro, P.; Claudio, N.; Salio, M.; Falcone, M.; Cenderello, G.; Donghi, L.; Del Bono, V.; Colombelli, P.L.; Angheben, A.; Passaro, A.; Secondo, G.; Pascale, R.; Piazza, I.; Facciolongo, N.; Costantini, M. Effect of tocilizumab vs. standard care on clinical worsening in patients hospitalized with COVID-19 pneumonia: A randomized clinical trial. JAMA Intern. Med., 2021, 181(1), 24-31. doi: 10.1001/jamainternmed.2020.6615 PMID: 33080005
- Hermine, O.; Mariette, X.; Tharaux, P.L.; Resche-Rigon, M.; Porcher, R.; Ravaud, P.; Bureau, S.; Dougados, M.; Tibi, A.; Azoulay, E.; Cadranel, J.; Emmerich, J.; Fartoukh, M.; Guidet, B.; Humbert, M.; Lacombe, K.; Mahevas, M.; Pene, F.; Pourchet-Martinez, V.; Schlemmer, F.; Yazdanpanah, Y.; Baron, G.; Perrodeau, E.; Vanhoye, D.; Kedzia, C.; Demerville, L.; Gysembergh-Houal, A.; Bourgoin, A.; Dalibey, S.; Resche-Rigon, M.; Raked, N.; Mameri, L.; Alary, S.; Hamiria, S.; Bariz, T.; Semri, H.; Hai, D.M.; Benafla, M.; Belloul, M.; Vauboin, P.; Flamand, S.; Pacheco, C.; Walter-Petrich, A.; Stan, E.; Benarab, S.; Nyanou, C.; Montlahuc, C.; Biard, L.; Charreteur, R.; Dupré, C.; Cardet, K.; Lehmann, B.; Baghli, K.; Madeleine, C.; DOrtenzio, E.; Puéchal, O.; Semaille, C.; Savale, L.; Harrois, A.; Figueiredo, S.; Duranteau, J.; Anguel, N.; Monnet, X.; Richard, C.; Teboul, J-L.; Durand, P.; Tissieres, P.; Jevnikar, M.; Montani, D.; Pavy, S.; Noel, N.; Lambotte, O.; Escaut, L.; Jauréguiberry, S.; Baudry, E.; Verny, C.; Lefèvre, E.; Zaidan, M.; Le Tiec, C.L.T.; Verstuyft, C.V.; Roques, A-M.; Grimaldi, L.; Molinari, D.; Leprun, G.; Fourreau, A.; Cylly, L.; Virlouvet, M.; Meftali, R.; Fabre, S.; Licois, M.; Mamoune, A.; Boudali, Y.; Georgin-Lavialle, S.; Senet, P.; Soria, A.; Parrot, A.; François, H.; Rozensztajn, N.; Blin, E.; Choinier, P.; Camuset, J.; Rech, J-S.; Canellas, A.; Rolland-Debord, C.; Lemarié, N.; Belaube, N.; Nadal, M.; Siguier, M.; Petit-Hoang, C.; Chas, J.; Drouet, E.; Lemoine, M.; Phibel, A.; Aunay, L.; Bertrand, E.; Ravato, S.; Vayssettes, M.; Adda, A.; Wilpotte, C.; Thibaut, P.; Fillon, J.; Debrix, I.; Fellahi, S.; Bastard, J-P.; Lefèvre, G.; Fallet, V.; Gottenberg, J-E.; Hansmann, Y.; Andres, E.; Bayer, S.; Becker, G.; Blanc, F.; Brin, S.; Castelain, V.; Chatelus, E.; Chatron, E.; Collange, O.; Danion, F.; De Blay, F.; Demonsant, E.; Diemunsch, P.; Diemunsch, S.; Felten, R.; Goichot, B.; Greigert, V.; Guffroy, A.; Heger, B.; Hutt, A.; Kaeuffer, C.; Kassegne, L.; Korganow, A.S.; Le Borgne, P.; Lefebvre, N.; Martin, T.; Mertes, P.M.; Metzger, C.; Meyer, N.; Nisand, G.; Noll, E.; Oberlin, M.; Ohlmann-Caillard, S.; Poindron, V.; Pottecher, J.; Ruch, Y.; Sublon, C.; Tayebi, H.; Weill, F.; Mekinian, A.; Chopin, D.; Fain, O.; Garnier, M.; Krause Le Garrec, J.; Morgand, M.; Pacanowski, J.; Urbina, T.; Mcavoy, C.; Pereira, M.; Aratus, G.; Berard, L.; Simon, T.; Daguenel Nguyen, A.; Antignac, M.; Leplay, C.; Arlet, J-B.; Diehl, J-L.; Bellenfant, F.; Blanchard, A.; Buffet, A.; Cholley, B.; Fayol, A.; Flamarion, E.; Godier, A.; Gorget, T.; Hamada, S-R.; Hauw-Berlemont, C.; Hulot, J-S.; Lebeaux, D.; Livrozet, M.; Michon, A.; Neuschwander, A.; Penet, M-A.; Planquette, B.; Ranque, B.; Sanchez, O.; Volle, G.; Briois, S.; Cornic, M.; Elisee, V.; Jesuthasan, D.; Djadi-Prat, J.; Jouany, P.; Junquera, R.; Henriques, M.; Kebir, A.; Lehir, I.; Meunier, J.; Patin, F.; Paquet, V.; TréHan, A.; Vigna, V.; Sabatier, B.; Bergerot, D.; Jouve, C.; Knosp, C.; Lenoir, O.; Mahtal, N.; Resmini, L.; Lescure, X.; Ghosn, J.; Bachelard, A.; Bironne, T.; Borie, R.; Bounhiol, A.; Boussard, C.; Chauffier, J.; Chalal, S.; Chalal, L.; Chansombat, M.; Crespin, P.; Crestani, B.; Daconceicao, O.; Deconinck, L.; Dieude; Dossier, A.; Dubert, M.; Ducrocq, G.; Fuentes, A.; Gervais, A.; Gilbert, M.; Isernia, V.; Ismael, S.; Joly, V.; Julia, Z.; Lariven, S.; Le Gac, S.; Le Pluart, D.; Louni, F.; Ndiaye, A.; Papo, T.; Parisey, M.; Phung, B.; Pourbaix, A.; Rachline, A.; Rioux, C.; Sautereau, A.; Steg, G.; Tharini, H.; Valayer, S.; Vallois, D.; Vermes, P.; Volpe, T.; Nguyen, Y.; Honsel, V.; Weiss, E.; Codorniu, A.; Zarrouk, V.; De Lastours, V.; Uzzan, M.; Gamany, N.; Rahli, R.; Louis, Z.; Boutboul, D.; Galicier, L.; Amara, Y.; Archer, G.; Benattia, A.; Bergeron, A.; Bondeelle, L.; De Castro, N.; Clément, M.; Darmont, M.; Denis, B.; Dupin, C.; Feredj, E.; Feyeux, D.; Joseph, A.; Lengliné, E.; Le Guen, P.; Liégeon, G.; Lorillon, G.; Mabrouki, A.; Mariotte, E.; Martin De Frémont, G.; Mirouse, A.; Molina, J-M.; Peffault De Latour, R.; Oksenhendler, E.; Saussereau, J.; Tazi, A.; Tudesq, J-J.; Zafrani, L.; Brindele, I.; Bugnet, E.; Celli Lebras, K.; Chabert, J.; Djaghout, L.; Fauvaux, C.; Jegu, A.L.; Kozaliewicz, E.; Meunier, M.; Tremorin, M-T.; Davoine, C.; Madeleine, I.; Caillat-Zucman, S.; Delaugerre, C.; Morin, F.; Sene, D.; Burlacu, R.; Chousterman, B.; Megarbane, B.; Richette, P.; Riveline, J-P.; Frazier, A.; Vicaut, E.; Berton, L.; Hadjam, T.; Vasquez-Ibarra, M.A.; Jourdaine, C.; Jacob, A.; Smati, J.; Renaud, S.; Manivet, P.; Pernin, C.; Suarez, L.; Semerano, L.; Abad, S.; Benainous, R.; Bloch Queyrat, C.; Bonnet, N.; Brahmi, S.; Cailhol; Cohen, Y.; Comparon, C.; Cordel, H.; Dhote, R.; Dournon, N.; Duchemann, B.; Ebstein, N.; Giroux-Leprieur, B.; Goupil De Bouille, J.; Jacolot, A.; Nunes, H.; Oziel, J.; Rathouin, V.; Rigal, M.; Roulot, D.; Tantet, C.; Uzunhan, Y.; Costedoat-Chalumeau, N.; Ait Hamou, Z.; Benghanem, S.; Blanche, P.; Canoui, E.; Carlier, N.; Chaigne, B.; Contejean, A.; Dunogue, B.; Dupland, P.; Durel - Maurisse, A.; Gauzit, R.; Jaubert, P.; Joumaa, H.; Jozwiak, M.; Kerneis, S.; Lachatre, M.; Lafoeste, H.; Legendre, P.; Luong Nguyen, L.B.; Marey, J.; Morbieu, C.; Mouthon, L.; Nguyen, L.; Palmieri, L-J.; Regent, A.; Szwebel, T-A.; Terrier, B.; Guerin, C.; Zerbit, J.; Cheref, K.; Chitour, K.; Cisse, M.S.; Clarke, A.; Clavere, G.; Dusanter, I.; Gaudefroy, C.; Jallouli, M.; Kolta, S.; Le Bourlout, C.; Marin, N.; Menage, N.; Moores, A.; Peigney, I.; Pierron, C.; Saleh-Mghir, S.; Vallet, M.; Michel, M.; Melica, G.; Lelievre, J-D.; Fois, E.; Lim, P.; Matignon, M.; Guillaud, C.; Thiemele, A.; Schmitz, D.; Bouhris, M.; Belazouz, S.; Languille, L.; Mekontso-Dessaps, A.; Sadaoui, T.; Mayaux, J.; Cacoub, P.; Corvol, J-C.; Louapre, C.; Sambin, S.; Mariani, L-L.; Karachi, C.; Tubach, F.; Estellat, C.; Gimeno, L.; Martin, K.; Bah, A.; Keo, V.; Ouamri, S.; Messaoudi, Y.; Yelles, N.; Faye, P.; Cavelot, S.; Larcheveque, C.; Annonay, L.; Benhida, J.; Zahrate-Ghoul, A.; Hammal, S.; Belilita, R.; Lecronier, M.; Beurton, A.; Haudebourg, L.; Deleris, R.; Le Marec, J.; Virolle, S.; Nemlaghi, S.; Bureau, C.; Mora, P.; De Sarcus, M.; Clovet, O.; Duceau, B.; Grisot, P.H.; Pari, M.; Arzoine, J.; Clarac, U.; Faure, M.; Delemazure, J.; Decavele, M.; Morawiec, E.; Demoule, A.; Dres, M.; Vautier, M.; Allenbach, Y.; Benveniste, O.; Leroux, G.; Rigolet, A.; Guillaume-Jugnot, P.; Domont, F.; Desbois, A.C.; Comarmond, C.; Champtiaux, N.; Toquet, S.; Ghembaza, A.; Vieira, M.; Maalouf, G.; Boleto, G.; Ferfar, Y.; Charbonnier, F.; Aguilar, C.; Alby-Laurent, F.; Alyanakian, M-A.; Bakouboula, P.; Broissand, C.; Burger, C.; Campos-Vega, C.; Chavarot, N.; Choupeaux, L.; Elie, C.; Fournier, B.; Granville, S.; Issorat, E.; Rouzaud, C.; Vimpere, D.; Geri, G.; Derridj, N.; Sguiouar, N.; Meddah, H.; Djadel, M.; Chambrin-Lauvray, H.; Duclos-Vallée, J-C.; Saliba, F.; Sacleux, S-C.; Koumis, I.; Michot, J-M.; Stoclin, A.; Colomba, E.; Pommeret, F.; Willekens, C.; Da Silva, R.; Dejean, V.; Mekid, Y.; Ben-Mabrouk, I.; Pradon, C.; Drouard, L.; Camara-Clayette, V.; Morel, A.; Garcia, G.; Mohebbi, A.; Berbour, F.; Dehais, M.; Pouliquen, A-L.; Klasen, A.; Soyez-Herkert, L.; London, J.; Keroumi, Y.; Guillot, E.; Grailles, G.; El Amine, Y.; Defrancq, F.; Fodil, H.; Bouras, C.; Dautel, D.; Gambier, N.; Dieye, T.; Bienvenu, B.; Lancon, V.; Lecomte, L.; Beziriganyan, K.; Asselate, B.; Allanic, L.; Kiouris, E.; Legros, M-H.; Lemagner, C.; Martel, P.; Provitolo, V.; Ackermann, F.; Le Marchand, M.; Clan Hew Wai, A.; Fremont, D.; Coupez, E.; Adda, M.; Duée, F.; Bernard, L.; Gros, A.; Henry, E.; Courtin, C.; Pattyn, A.; Guinot, P-G.; Bardou, M.; Maurer, A.; Jambon, J.; Cransac, A.; Pernot, C.; Mourvillier, B.; Servettaz, A.; Deslée, G.; Wynckel, A.; Benoit, P.; Marquis, E.; Roux, D.; Gernez, C.; Yelnik, C.; Poissy, J.; Nizard, M.; Denies, F.; Gros, H.; Mourad, J-J.; Sacco, E.; Renet, S. Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: A randomized clinical trial. JAMA Intern. Med., 2021, 181(1), 32-40. doi: 10.1001/jamainternmed.2020.6820 PMID: 33080017
- Gordon, A.C.; Angus, D.C.; Derde, L.P.G. Interleukin-6 receptor antagonists in critically Ill patients with Covid-19. N. Engl. J. Med., 2021, 385(12), 1147-1149. doi: 10.1056/NEJMc2108482 PMID: 34407335
- Jeronimo, C.M.P.; Farias, M.E.L.; Val, F.F.A.; Sampaio, V.S.; Alexandre, M.A.A.; Melo, G.C.; Safe, I.P.; Borba, M.G.S.; Netto, R.L.A.; Maciel, A.B.S.; Neto, J.R.S.; Oliveira, L.B.; Figueiredo, E.F.G.; Oliveira Dinelly, K.M.; de Almeida Rodrigues, M.G.; Brito, M.; Mourão, M.P.G.; Pivoto João, G.A.; Hajjar, L.A.; Bassat, Q.; Romero, G.A.S.; Naveca, F.G.; Vasconcelos, H.L.; de Araújo Tavares, M.; Brito-Sousa, J.D.; Costa, F.T.M.; Nogueira, M.L.; Baía-da-Silva, D.C.; Xavier, M.S.; Monteiro, W.M.; Lacerda, M.V.G.; de Lemos Vasconcelos, A.; Praia Marins, A.F.; de Oliveira Trindade, A.; Mendes Záu, A.S.; de Oliveira, A.C.; Azevedo Furtado, A.C.; Coelho Rocha, A.P.; da Silva Souza, A.; de Souza Dias, A.; Belém, A.; dos Santos, A.G.R.; da Silva Sousa, A.M.; da Silva, B.F.; Franco, B.L.; da Silva, B.M.; da Costa, B.L.G.; Sato Barros do Amaral, C.M.S.; Judice, C.C.; de Morais, C.E.P.; Camilo, C.C.; Sena da Silva, D.S.; Gomes Duarte, D.C.; da Silva, E.G.N.; da Silva Lemos, E.; de Fátima Ponte Frota, E.; do Nascimento, E.F.; de Almeida, E.S.; Marques, E.A.; de Almeida, E.M.M.; da Silva, E.L.; dos Santos, E.G.; da Silva Oliveira, E.; Martins Shimizu, F.M.; de Souza, F.R.F.; da Silva do Vale, F.; dos Santos de Almeida Lima, F.; da Fonseca, F.H.J.; Fontenelle, F.A.; de Azevedo Furtado, F.; Da Silva Pereira, G.; Bezerra, G.A.; Maciel Salazar, G.K.; da Silva Pereira, H.; de Melo, H.F.; Oliveira, I.N.; Pereira Filho, I.V.; Gomes, J.V.; e Silva Rosa, J.; Lemos, J.M.; Brutus, J.N.; Pessoa, K.P.; Costa Rodrigues, L.D.; Barros Cirino, L.E.; Mourão Filho, L.F.; Moura, L.; Barbosa, L.R.P.; de Souza, L.P.; Oliveira, L.B.; de Lima Ferreira, L.C.; dos Santos, M.M.; da Silva, M.V.R.; Rodrigues, M.P.; de Menezes, M.T.; dos Santos Mota, M.M.; Freire, M.; Corrêa, N.F.; Rocha, N.M.; Bittencourt, N.; de Melo Silva, N.G.; de Oliveira Saraiva, P.; de Sousa Monteiro, Q.; dos Santos, R.T.; Freire, R.S.; de Araújo Pinto, R.A.; Ferreira, R.B.; de Lima, R.S.; de Melo, R.F.T.; Saenz, S.T.; Alvarez Fernandes, S.S.; Vítor-Silva, S.; de Oliveira, T.M.R.; Tavella, T.A.; Câmara, T.T.; Santos, T.C.; Pinto, T.S.; dos Santos, T.W.R.; do Nascimento, V.A.; Sousa, B.W.P.; de Melo, W.F.; Salgado, S.W.B. Methylprednisolone as adjunctive therapy for patients hospitalized with coronavirus disease 2019 (COVID-19; Metcovid): A randomized, double-blind, phase IIb, placebo-controlled trial. Clin. Infect. Dis., 2021, 72(9), e373-e381. doi: 10.1093/cid/ciaa1177 PMID: 32785710
- Favalli, E.G.; Ingegnoli, F.; De Lucia, O.; Cincinelli, G.; Cimaz, R.; Caporali, R. COVID-19 infection and rheumatoid arthritis: Faraway, so close! Autoimmun. Rev., 2020, 19(5), 102523. doi: 10.1016/j.autrev.2020.102523 PMID: 32205186
- Ma, J.; Muheem, A.; Rizvi, M. Coronavirus (COVID-19): History, current knowledge and pipeline medications. Int. J. Pharm., 2020, 4(1), 1-9. doi: 10.31531/2581-3080.1000140
- Pei, J.; Sekellick, M.J.; Marcus, P.I.; Choi, I.S.; Collisson, E.W. Chicken interferon type I inhibits infectious bronchitis virus replication and associated respiratory illness. J. Interferon Cytokine Res., 2001, 21(12), 1071-1077. doi: 10.1089/107999001317205204 PMID: 11798465
- Chen, F.; Chan, K.H.; Jiang, Y.; Kao, R.Y.T.; Lu, H.T.; Fan, K.W.; Cheng, V.C.C.; Tsui, W.H.W.; Hung, I.F.N.; Lee, T.S.W.; Guan, Y.; Peiris, J.S.; Yuen, K.Y. In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compounds. J. Clin. Virol., 2004, 31(1), 69-75. doi: 10.1016/j.jcv.2004.03.003 PMID: 15288617
- Kuri, T.; Zhang, X.; Habjan, M.; Martínez-Sobrido, L.; García-Sastre, A.; Yuan, Z.; Weber, F. Interferon priming enables cells to partially overturn the SARS coronavirus-induced block in innate immune activation. J. Gen. Virol., 2009, 90(11), 2686-2694. doi: 10.1099/vir.0.013599-0 PMID: 19625461
- Tan, E.L.C.; Ooi, E.E.; Lin, C.Y.; Tan, H.C.; Ling, A.E.; Lim, B.; Stanton, L.W. Inhibition of SARS coronavirus infection in vitro with clinically approved antiviral drugs. Emerg. Infect. Dis., 2004, 10(4), 581-586. doi: 10.3201/eid1004.030458 PMID: 15200845
- Manns, M.P.; McHutchison, J.G.; Gordon, S.C.; Rustgi, V.K.; Shiffman, M.; Reindollar, R.; Goodman, Z.D.; Koury, K.; Ling, M.H.; Albrecht, J.K. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial. Lancet, 2001, 358(9286), 958-965. doi: 10.1016/S0140-6736(01)06102-5 PMID: 11583749
- Deng, X.; Yu, X.; Pei, J. Regulation of interferon production as a potential strategy for COVID-19 treatment. arXiv, 2020, 2003.00751.
- Omrani, A.S.; Saad, M.M.; Baig, K.; Bahloul, A.; Abdul-Matin, M.; Alaidaroos, A.Y.; Almakhlafi, G.A.; Albarrak, M.M.; Memish, Z.A.; Albarrak, A.M. Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: A retrospective cohort study. Lancet Infect. Dis., 2014, 14(11), 1090-1095. doi: 10.1016/S1473-3099(14)70920-X PMID: 25278221
- Kalil, A.C. Treating COVID-19off-label drug use, compassionate use, and randomized clinical trials during pandemics. JAMA, 2020, 323(19), 1897-1898. doi: 10.1001/jama.2020.4742 PMID: 32208486
- Gautret, P.; Lagier, J.C.; Honoré, S.; Hoang, V.T.; Colson, P.; Raoult, D.; Courjon, J.; Giordanengo, V.; Vieira, V.E.; Dupont, H.T. Hydroxychloroquine and azithromycin as a treatment of COVID-19: Results of an open label non-randomized clinical trial revisited. Int. J. Antimicrob. Agents, 2021, 57(1), 106243. doi: 10.1016/j.ijantimicag.2020.106243 PMID: 33408014
- Gautret, P.; Lagier, J.C.; Parola, P.; Hoang, V.T.; Meddeb, L.; Sevestre, J.; Mailhe, M.; Doudier, B.; Aubry, C.; Amrane, S.; Seng, P.; Hocquart, M.; Eldin, C.; Finance, J.; Vieira, V.E.; Tissot-Dupont, H.T.; Honoré, S.; Stein, A.; Million, M.; Colson, P.; La Scola, B.; Veit, V.; Jacquier, A.; Deharo, J.C.; Drancourt, M.; Fournier, P.E.; Rolain, J.M.; Brouqui, P.; Raoult, D. Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: A pilot observational study. Travel Med. Infect. Dis., 2020, 34, 101663. doi: 10.1016/j.tmaid.2020.101663 PMID: 32289548
- Javelot, H.; El-Hage, W.; Meyer, G.; Becker, G.; Michel, B.; Hingray, C. COVID-19 and (hydroxy)chloroquineazithromycin combination: Should we take the risk for our patients? Br. J. Clin. Pharmacol., 2020, 86(6), 1176-1177. doi: 10.1111/bcp.14335 PMID: 32350872
- Gbinigie, K.; Frie, K. Should azithromycin be used to treat COVID-19? A rapid review. BMJ open, 2020, 4(2), bjgpopen20X101094. doi: 10.3399/bjgpopen20X101094
- Andreani, J.; Le Bideau, M.; Duflot, I.; Jardot, P.; Rolland, C.; Boxberger, M.; Wurtz, N.; Rolain, J.M.; Colson, P.; La Scola, B.; Raoult, D. In vitro testing of combined hydroxychloroquine and azithromycin on SARS-CoV-2 shows synergistic effect. Microb. Pathog., 2020, 145, 104228. doi: 10.1016/j.micpath.2020.104228 PMID: 32344177
- Arikata, M.; Itoh, Y.; Shichinohe, S.; Nakayama, M.; Ishigaki, H.; Kinoshita, T.; Le, M.Q.; Kawaoka, Y.; Ogasawara, K.; Shimizu, T. Efficacy of clarithromycin against H5N1 and H7N9 avian influenza a virus infection in cynomolgus monkeys. Antiviral Res., 2019, 171, 104591. doi: 10.1016/j.antiviral.2019.104591 PMID: 31421167
- Takahashi, E.; Indalao, I.L.; Sawabuchi, T.; Mizuno, K.; Sakai, S.; Kimoto, T.; Kim, H.; Kido, H. Clarithromycin suppresses induction of monocyte chemoattractant protein-1 and matrix metalloproteinase-9 and improves pathological changes in the lungs and heart of mice infected with influenza A virus. Comp. Immunol. Microbiol. Infect. Dis., 2018, 56, 6-13. doi: 10.1016/j.cimid.2017.11.002 PMID: 29406285
- Amsden, G. Erythromycin, clarithromycin, and azithromycin: Are the differences real? Clin. Ther., 1996, 18(1), 56-72. doi: 10.1016/S0149-2918(96)80179-2 PMID: 8851453
- Millán-Oñate, J.; Millan, W.; Mendoza, L.A.; Sánchez, C.G.; Fernandez-Suarez, H.; Bonilla-Aldana, D.K.; Rodríguez-Morales, A.J. Successful recovery of COVID-19 pneumonia in a patient from Colombia after receiving chloroquine and clarithromycin. Ann. Clin. Microbiol. Antimicrob., 2020, 19(1), 16. doi: 10.1186/s12941-020-00358-y PMID: 32331519
- Zhou, N.; Pan, T.; Zhang, J.; Li, Q.; Zhang, X.; Bai, C.; Huang, F.; Peng, T.; Zhang, J.; Liu, C.; Tao, L.; Zhang, H. Glycopeptide antibiotics potently inhibit cathepsin l in the late endosome/lysosome and block the entry of ebola virus, middle east respiratory syndrome coronavirus (MERS-CoV), and severe acute respiratory syndrome coronavirus (SARS-CoV). J. Biol. Chem., 2016, 291(17), 9218-9232. doi: 10.1074/jbc.M116.716100 PMID: 26953343
- Wang, Y.; Cui, R.; Li, G.; Gao, Q.; Yuan, S.; Altmeyer, R.; Zou, G. Teicoplanin inhibits Ebola pseudovirus infection in cell culture. Antiviral Res., 2016, 125, 1-7. doi: 10.1016/j.antiviral.2015.11.003 PMID: 26585243
- Baron, S.A.; Devaux, C.; Colson, P.; Raoult, D.; Rolain, J.M. Teicoplanin: An alternative drug for the treatment of COVID-19? Int. J. Antimicrob. Agents, 2020, 55(4), 105944. doi: 10.1016/j.ijantimicag.2020.105944 PMID: 32179150
- Ceccarelli, G.; Alessandri, F.; dEttorre, G.; Borrazzo, C.; Spagnolello, O.; Oliva, A.; Ruberto, F.; Mastroianni, C.M.; Pugliese, F.; Venditti, M. Is teicoplanin a complementary treatment option for COVID-19? The question remains. Int. J. Antimicrob. Agents, 2020, 56(2), 106029. doi: 10.1016/j.ijantimicag.2020.106029 PMID: 32454071
- Fredeking, T.; Zavala-Castro, J.; González-Martínez, P.; Moguel-Rodríguez, W.; Sanchez, E.; Foster, M.; Diaz-Quijano, F. Dengue patients treated with doxycycline showed lower mortality associated to a reduction in IL-6 and TNF levels. Recent Patents Anti-Infect. Drug Disc., 2015, 10(1), 51-58. doi: 10.2174/1574891X10666150410153839 PMID: 25858261
- Mehta, P.; McAuley, D.F.; Brown, M.; Sanchez, E.; Tattersall, R.S.; Manson, J.J. COVID-19: Consider cytokine storm syndromes and immunosuppression. Lancet, 2020, 395(10229), 1033-1034. doi: 10.1016/S0140-6736(20)30628-0 PMID: 32192578
- Quartuccio, L.; Semerano, L.; Benucci, M.; Boissier, M.C.; De Vita, S. Urgent avenues in the treatment of COVID-19: Targeting downstream inflammation to prevent catastrophic syndrome. Joint Bone Spine, 2020, 87(3), 191-193. doi: 10.1016/j.jbspin.2020.03.011 PMID: 32321634
- Wu, C.; Liu, Y.; Yang, Y.; Zhang, P.; Zhong, W.; Wang, Y.; Wang, Q.; Xu, Y.; Li, M.; Li, X.; Zheng, M.; Chen, L.; Li, H. Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods. Acta Pharm. Sin. B, 2020, 10(5), 766-788. doi: 10.1016/j.apsb.2020.02.008 PMID: 32292689
- De Clercq, E. Potential antivirals and antiviral strategies against SARS coronavirus infections. Expert Rev. Anti Infect. Ther., 2006, 4(2), 291-302. doi: 10.1586/14787210.4.2.291 PMID: 16597209
- Wang, J. Fast identification of possible drug treatment of coronavirus disease-19 (COVID-19) through computational drug repurposing study. J. Chem. Inf. Model., 2020, 60(6), 3277-3286. doi: 10.1021/acs.jcim.0c00179 PMID: 32315171
- Thiem, U.; Heppner, H.J.; Pientka, L. Elderly patients with community-acquired pneumonia: optimal treatment strategies. Drugs Aging, 2011, 28(7), 519-537. doi: 10.2165/11591980-000000000-00000 PMID: 21721597
- Durojaiye, A.B.; Clarke, J.R.D.; Stamatiades, G.A.; Wang, C. Repurposing cefuroxime for treatment of COVID-19: A scoping review of in silico studies. J. Biomol. Struct. Dyn., 2021, 39(12), 4547-4554. doi: 10.1080/07391102.2020.1777904 PMID: 32538276
- Almutairi, A.S.; Abunurah, H.; Hadi Alanazi, A.; Alenezi, F.K.; Nagy, H.; Saad Almutairi, N.; Wells, M.; Alawam, A.; Alqahtani, M.M. The immunological response among COVID-19 patients with acute respiratory distress syndrome. J. Infect. Public Health, 2021, 14(7), 954-959. doi: 10.1016/j.jiph.2021.05.007 PMID: 34130119
- van Paassen, J.; Vos, J.S.; Hoekstra, E.M.; Neumann, K.M.I.; Boot, P.C.; Arbous, S.M. Corticosteroid use in COVID-19 patients: A systematic review and meta-analysis on clinical outcomes. Crit. Care, 2020, 24(1), 696. doi: 10.1186/s13054-020-03400-9 PMID: 33317589
- Cheng, B.; Ma, J.; Yang, Y.; Shao, T.; Zhao, B.; Zeng, L. Systemic corticosteroid administration in coronavirus disease 2019 outcomes: An umbrella meta-analysis incorporating both mild and pulmonary fibrosismanifested severe disease. Front. Pharmacol., 2021, 12, 670170. doi: 10.3389/fphar.2021.670170 PMID: 34122093
- Horby, P.; Lim, W.S.; Emberson, J.R.; Mafham, M.; Bell, J.L.; Linsell, L.; Staplin, N.; Brightling, C.; Ustianowski, A.; Elmahi, E.; Prudon, B.; Green, C.; Felton, T.; Chadwick, D.; Rege, K.; Fegan, C.; Chappell, L.C.; Faust, S.N.; Jaki, T.; Jeffery, K.; Montgomery, A.; Rowan, K.; Juszczak, E.; Baillie, J.K.; Haynes, R.; Landray, M.J. Dexamethasone in hospitalized patients with covid-19. N. Engl. J. Med., 2021, 384(8), 693-704. doi: 10.1056/NEJMoa2021436 PMID: 32678530
- Kluge, S.; Janssens, U.; Welte, T.; Weber-Carstens, S.; Schälte, G.; Spinner, C.D.; Malin, J.J.; Gastmeier, P.; Langer, F.; Wepler, M.; Westhoff, M.; Pfeifer, M.; Rabe, K.F.; Hoffmann, F.; Böttiger, B.W.; Weinmann-Menke, J.; Kersten, A.; Berlit, P.; Haase, R.; Marx, G.; Karagiannidis, C. S2k-Leitlinie empfehlungen zur stationären therapie von patienten mit COVID-19. Pneumologie, 2021, 75(2), 88-112. doi: 10.1055/a-1334-1925 PMID: 33450783
- Daminova, N. The European medicines agency transparency policies, the CJEU and COVID-19: Do the CFREU provisions retain any relevance? MTA LAW WORKING PAPERS, 2021, 1(8), 1-32.
- Bartoletti, M.; Azap, O.; Barac, A.; Bussini, L.; Ergonul, O.; Krause, R.; Paño-Pardo, J.R.; Power, N.R.; Sibani, M.; Szabo, B.G.; Tsiodras, S.; Verweij, P.E.; Zollner-Schwetz, I.; Rodríguez-Baño, J. ESCMID COVID-19 living guidelines: Drug treatment and clinical management. Clin Microbiol Infect, 2022, 28(2), 222-238. doi: 10.1016/j.cmi.2021.11.007
- Wu, C.; Chen, X.; Cai, Y.; Xia, J.; Zhou, X.; Xu, S.; Huang, H.; Zhang, L.; Zhou, X.; Du, C.; Zhang, Y.; Song, J.; Wang, S.; Chao, Y.; Yang, Z.; Xu, J.; Zhou, X.; Chen, D.; Xiong, W.; Xu, L.; Zhou, F.; Jiang, J.; Bai, C.; Zheng, J.; Song, Y. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern. Med., 2020, 180(7), 934-943. doi: 10.1001/jamainternmed.2020.0994 PMID: 32167524
- Russell, C.D.; Millar, J.E.; Baillie, J.K. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet, 2020, 395(10223), 473-475. doi: 10.1016/S0140-6736(20)30317-2 PMID: 32043983
- Bahl, A.; Johnson, S.; Chen, N.W. Timing of corticosteroids impacts mortality in hospitalized COVID-19 patients. Intern. Emerg. Med., 2021, 16(6), 1593-1603. doi: 10.1007/s11739-021-02655-6 PMID: 33547620
- Bretagne, S.; Sitbon, K.; Botterel, F.; Dellière, S.; Letscher-Bru, V.; Chouaki, T.; Bellanger, A.P.; Bonnal, C.; Fekkar, A.; Persat, F.; Costa, D.; Bourgeois, N.; Dalle, F.; Lussac-Sorton, F.; Paugam, A.; Cassaing, S.; Hasseine, L.; Huguenin, A.; Guennouni, N.; Mazars, E.; Le Gal, S.; Sasso, M.; Brun, S.; Cadot, L.; Cassagne, C.; Cateau, E.; Gangneux, J.P.; Moniot, M.; Roux, A.L.; Tournus, C.; Desbois-Nogard, N.; Le Coustumier, A.; Moquet, O.; Alanio, A.; Dromer, F. COVID-19-associated pulmonary aspergillosis, fungemia, and pneumocystosis in the intensive care unit: A retrospective multicenter observational cohort during the first French pandemic wave. Microbiol. Spectr., 2021, 9(2), e01138-21. doi: 10.1128/Spectrum.01138-21 PMID: 34668768
- Li, H.; Chen, C.; Hu, F.; Wang, J.; Zhao, Q.; Gale, R.P.; Liang, Y. Impact of corticosteroid therapy on outcomes of persons with SARS-CoV-2, SARS-CoV, or MERS-CoV infection: A systematic review and meta-analysis. Leukemia, 2020, 34(6), 1503-1511. doi: 10.1038/s41375-020-0848-3 PMID: 32372026
- Budhathoki, P.; Shrestha, D.B.; Rawal, E.; Khadka, S. Corticosteroids in COVID-19: Is it rational? A systematic review and meta-analysis. SN Compr. Clin. Med., 2020, 2(12), 2600-2620. doi: 10.1007/s42399-020-00515-6 PMID: 33103063
- Day, M. Covid-19: European drugs agency to review safety of ibuprofen. BMJ, 2020, 368, m1168. doi: 10.1136/bmj.m1168 PMID: 32205306
- Little, P. Non-steroidal anti-inflammatory drugs and covid-19. BMJ, 2020, 368, m1185. doi: 10.1136/bmj.m1185 PMID: 32220865
- McManus, N.; Offman, R.; Oetman, J. Emergency department management of COVID-19: An evidence-based approach. West. J. Emerg. Med., 2020, 21(6), 32-44. doi: 10.5811/westjem.2020.8.48288 PMID: 33052814
- Amici, C.; Caro, A.D.; Ciucci, A.; Chiappa, L.; Castilletti, C.; Martella, V.; Decaro, N.; Buonavoglia, C.; Capobianchi, M.R.; Santoro, M.G. Indomethacin has a potent antiviral activity against SARS coronavirus. Antivir. Ther., 2006, 11(8), 1021-1030. doi: 10.1177/135965350601100803 PMID: 17302372
- Patel, A.B.; Verma, A. COVID-19 and angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: what is the evidence? JAMA, 2020, 323(18), 1769-1770. doi: 10.1001/jama.2020.4812 PMID: 32208485
- Sommerstein, R.; Kochen, M.M.; Messerli, F.H.; Gräni, C. Coronavirus disease 2019 (COVID-19): Do angiotensin-converting enzyme inhibitors/angiotensin receptor blockers have a biphasic effect? J. Am. Heart Assoc., 2020, 9(7), e016509. doi: 10.1161/JAHA.120.016509 PMID: 32233753
- Warner, F.J.; Smith, A.I.; Hooper, N.M.; Turner, A.J. Angiotensin-converting enzyme-2: A molecular and cellular perspective. Cell. Mol. Life Sci., 2004, 61(21), 2704-2713. doi: 10.1007/s00018-004-4240-7 PMID: 15549171
- Dimitrov, D.S. The secret life of ACE2 as a receptor for the SARS virus. Cell, 2003, 115(6), 652-653. doi: 10.1016/S0092-8674(03)00976-0 PMID: 14675530
- Li, W.; Moore, M.J.; Vasilieva, N.; Sui, J.; Wong, S.K.; Berne, M.A.; Somasundaran, M.; Sullivan, J.L.; Luzuriaga, K.; Greenough, T.C.; Choe, H.; Farzan, M. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature, 2003, 426(6965), 450-454. doi: 10.1038/nature02145 PMID: 14647384
- Simmons, G.; Reeves, J.D.; Rennekamp, A.J.; Amberg, S.M.; Piefer, A.J.; Bates, P. Characterization of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) spike glycoprotein-mediated viral entry. Proc. Natl. Acad. Sci., 2004, 101(12), 4240-4245. doi: 10.1073/pnas.0306446101 PMID: 15010527
- Yeung, K.S.; Yamanaka, G.A.; Meanwell, N.A. Severe acute respiratory syndrome coronavirus entry into host cells: Opportunities for therapeutic intervention. Med. Res. Rev., 2006, 26(4), 414-433. doi: 10.1002/med.20055 PMID: 16521129
- Diaz, J.H. Hypothesis: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may increase the risk of severe COVID-19. J. Travel Med., 2020, 27(3), taaa041. doi: 10.1093/jtm/taaa041 PMID: 32186711
- Rothan, H.A.; Byrareddy, S.N. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J. Autoimmun., 2020, 109, 102433. doi: 10.1016/j.jaut.2020.102433 PMID: 32113704
- Hussain, A.; Bhowmik, B.; do Vale Moreira, N.C. COVID-19 and diabetes: Knowledge in progress. Diabetes Res. Clin. Pract., 2020, 162, 108142. doi: 10.1016/j.diabres.2020.108142 PMID: 32278764
- Muniyappa, R.; Gubbi, S. COVID-19 pandemic, coronaviruses, and diabetes mellitus. Am. J. Physiol. Endocrinol. Metab., 2020, 318(5), E736-E741. doi: 10.1152/ajpendo.00124.2020 PMID: 32228322
- Allard, R.; Leclerc, P.; Tremblay, C.; Tannenbaum, T.N. Diabetes and the severity of pandemic influenza A (H1N1) infection. Diabetes Care, 2010, 33(7), 1491-1493. doi: 10.2337/dc09-2215 PMID: 20587722
- Targher, G.; Mantovani, A.; Wang, X.B.; Yan, H.D.; Sun, Q.F.; Pan, K.H.; Byrne, C.D.; Zheng, K.I.; Chen, Y.P.; Eslam, M.; George, J.; Zheng, M.H. Patients with diabetes are at higher risk for severe illness from COVID-19. Diabetes Metab., 2020, 46(4), 335-337. doi: 10.1016/j.diabet.2020.05.001 PMID: 32416321
- Fadini, G.P.; Morieri, M.L.; Longato, E.; Avogaro, A. Prevalence and impact of diabetes among people infected with SARS-CoV-2. J. Endocrinol. Invest., 2020, 43(6), 867-869. doi: 10.1007/s40618-020-01236-2 PMID: 32222956
- Guo, W.; Li, M.; Dong, Y.; Zhou, H.; Zhang, Z.; Tian, C.; Qin, R.; Wang, H.; Shen, Y.; Du, K.; Zhao, L.; Fan, H.; Luo, S.; Hu, D. Diabetes is a risk factor for the progression and prognosis of COVID -19. Diabetes Metab. Res. Rev., 2020, 36(7), e3319. doi: 10.1002/dmrr.3319 PMID: 32233013
- Stoian, A.P.; Banerjee, Y.; Rizvi, A.A.; Rizzo, M. Diabetes and the COVID-19 pandemic: How insights from recent experience might guide future management. Metab. Syndr. Relat. Disord., 2020, 18(4), 173-175. doi: 10.1089/met.2020.0037 PMID: 32271125
- Bornstein, S.R.; Dalan, R.; Hopkins, D.; Mingrone, G.; Boehm, B.O. Endocrine and metabolic link to coronavirus infection. Nat. Rev. Endocrinol., 2020, 16(6), 297-298. doi: 10.1038/s41574-020-0353-9 PMID: 32242089
- Sardu, C.; DOnofrio, N.; Balestrieri, M.L.; Barbieri, M.; Rizzo, M.R.; Messina, V.; Maggi, P.; Coppola, N.; Paolisso, G.; Marfella, R. Outcomes in patients with hyperglycemia affected by COVID-19: can we do more on glycemic control? Diabetes Care, 2020, 43(7), 1408-1415. doi: 10.2337/dc20-0723 PMID: 32430456
- Solerte, S.B.; DAddio, F.; Trevisan, R.; Lovati, E.; Rossi, A.; Pastore, I.; DellAcqua, M.; Ippolito, E.; Scaranna, C.; Bellante, R.; Galliani, S.; Dodesini, A.R.; Lepore, G.; Geni, F.; Fiorina, R.M.; Catena, E.; Corsico, A.; Colombo, R.; Mirani, M.; De Riva, C.; Oleandri, S.E.; Abdi, R.; Bonventre, J.V.; Rusconi, S.; Folli, F.; Di Sabatino, A.; Zuccotti, G.; Galli, M.; Fiorina, P. Sitagliptin treatment at the time of hospitalization was associated with reduced mortality in patients with type 2 diabetes and COVID-19: A multicenter, case-control, retrospective, observational study. Diabetes Care, 2020, 43(12), 2999-3006. doi: 10.2337/dc20-1521 PMID: 32994187
- Sun, Q.; Li, J.; Gao, F. New insights into insulin: The anti-inflammatory effect and its clinical relevance. World J. Diabetes, 2014, 5(2), 89-96. doi: 10.4239/wjd.v5.i2.89 PMID: 24765237
- Salem, E.S.B.; Grobe, N.; Elased, K.M. Insulin treatment attenuates renal ADAM17 and ACE2 shedding in diabetic Akita mice. Am. J. Physiol. Renal Physiol., 2014, 306(6), F629-F639. doi: 10.1152/ajprenal.00516.2013 PMID: 24452639
- Chen, Y.; Yang, D.; Cheng, B.; Chen, J.; Peng, A.; Yang, C.; Liu, C.; Xiong, M.; Deng, A.; Zhang, Y.; Zheng, L.; Huang, K. Clinical characteristics and outcomes of patients with diabetes and COVID-19 in association with glucose-lowering medication. Diabetes Care, 2020, 43(7), 1399-1407. doi: 10.2337/dc20-0660 PMID: 32409498
- Xian, H.; Liu, Y.; Nilsson, A.R.; Gatchalian, R.; Crother, T.R.; Tourtellotte, W.G.; Zhang, Y.; Aleman-Muench, G.R.; Lewis, G.; Chen, W. Metformin inhibition of mitochondrial ATP and DNA synthesis abrogates NLRP3 inflammasome activation and pulmonary inflammation. Immunity, 2021, 54(7), 1463-1477. e1411.. doi: 10.1016/j.immuni.2021.05.004
- Bramante, C.T.; Ingraham, N.E.; Murray, T.A.; Marmor, S.; Hovertsen, S.; Gronski, J.; McNeil, C.; Feng, R.; Guzman, G.; Abdelwahab, N.; King, S.; Tamariz, L.; Meehan, T.; Pendleton, K.M.; Benson, B.; Vojta, D.; Tignanelli, C.J. Metformin and risk of mortality in patients hospitalised with COVID-19: A retrospective cohort analysis. Lancet Healthy Longev., 2021, 2(1), e34-e41. doi: 10.1016/S2666-7568(20)30033-7 PMID: 33521772
- Lalau, J.D.; Al-Salameh, A.; Hadjadj, S.; Goronflot, T.; Wiernsperger, N.; Pichelin, M.; Allix, I.; Amadou, C.; Bourron, O.; Duriez, T.; Gautier, J.F.; Dutour, A.; Gonfroy, C.; Gouet, D.; Joubert, M.; Julier, I.; Larger, E.; Marchand, L.; Marre, M.; Meyer, L.; Olivier, F.; Prevost, G.; Quiniou, P.; Raffaitin-Cardin, C.; Roussel, R.; Saulnier, P.J.; Seret-Begue, D.; Thivolet, C.; Vatier, C.; Desailloud, R.; Wargny, M.; Gourdy, P.; Cariou, B. Metformin use is associated with a reduced risk of mortality in patients with diabetes hospitalised for COVID-19. Diabetes Metab., 2021, 47(5), 101216. doi: 10.1016/j.diabet.2020.101216 PMID: 33309936
- Luo, P.; Qiu, L.; Liu, Y.; Liu, X.; Zheng, J.; Xue, H.; Liu, W.; Liu, D.; Li, J. Metformin treatment was associated with decreased mortality in COVID-19 patients with diabetes in a retrospective analysis. Am. J. Trop. Med. Hyg., 2020, 103(1), 69-72. doi: 10.4269/ajtmh.20-0375 PMID: 32446312
- Apostolova, N.; Iannantuoni, F.; Gruevska, A.; Muntane, J.; Rocha, M.; Victor, V.M. Mechanisms of action of metformin in type 2 diabetes: Effects on mitochondria and leukocyte-endothelium interactions. Redox Biol., 2020, 34, 101517. doi: 10.1016/j.redox.2020.101517 PMID: 32535544
- Cheng, X.; Liu, Y.-M.; Li, H.; Zhang, X.; Lei, F.; Qin, J.-J.; Chen, Z.; Deng, K.-Q.; Lin, L.; Chen, M.-M. Metformin is associated with higher incidence of acidosis, but not mortality, in individuals with COVID-19 and pre-existing type 2 diabetes. Cell metabolism, 2020, 32(4), 537-547. e533.. doi: 10.1016/j.cmet.2020.08.013
- Gao, Y.; Liu, T.; Zhong, W.; Liu, R.; Zhou, H.; Huang, W.; Zhang, W. Risk of metformin in patients with type 2 diabetes with COVID-19: A preliminary retrospective report. Clin. Transl. Sci., 2020, 13(6), 1055-1059. doi: 10.1111/cts.12897 PMID: 32955785
- Apicella, M.; Campopiano, M.C.; Mantuano, M.; Mazoni, L.; Coppelli, A.; Del Prato, S. COVID-19 in people with diabetes: understanding the reasons for worse outcomes. Lancet Diabetes Endocrinol., 2020, 8(9), 782-792. doi: 10.1016/S2213-8587(20)30238-2 PMID: 32687793
- Katsiki, N.; Banach, M.; Mikhailidis, D. Lipid-lowering therapy and renin-angiotensin-aldosterone system inhibitors in the era of the COVID-19 pandemic. Arch. Med. Sci., 2020, 16(3), 485-489. doi: 10.5114/aoms.2020.94503 PMID: 32399093
- Pratelli, A.; Colao, V. Role of the lipid rafts in the life cycle of canine coronavirus. J. Gen. Virol., 2015, 96(2), 331-337. doi: 10.1099/vir.0.070870-0 PMID: 25381058
- Schönbeck, U.; Libby, P. Inflammation, immunity, and HMG-CoA reductase inhibitors: Statins as antiinflammatory agents? Circulation, 2004, 109(S21), II18-II26. doi: 10.1161/01.CIR.0000129505.34151.23 PMID: 15173059
- Baden, L.R.; Rubin, E.J. Covid-19 the search for effective therapy. N. Engl. J. Med., 2020, 382(19), 1851-1852. doi: 10.1056/NEJMe2005477 PMID: 32187463
- Tay, M.Y.F.; Fraser, J.E.; Chan, W.K.K.; Moreland, N.J.; Rathore, A.P.; Wang, C.; Vasudevan, S.G.; Jans, D.A. Nuclear localization of dengue virus (DENV) 14 non-structural protein 5; protection against all 4 DENV serotypes by the inhibitor Ivermectin. Antiviral Res., 2013, 99(3), 301-306. doi: 10.1016/j.antiviral.2013.06.002 PMID: 23769930
- Tu, Y.F.; Chien, C.S.; Yarmishyn, A.A.; Lin, Y.Y.; Luo, Y.H.; Lin, Y.T.; Lai, W.Y.; Yang, D.M.; Chou, S.J.; Yang, Y.P.; Wang, M.L.; Chiou, S.H. A review of SARS-CoV-2 and the ongoing clinical trials. Int. J. Mol. Sci., 2020, 21(7), 2657. doi: 10.3390/ijms21072657 PMID: 32290293
- Yang, S.N.Y.; Atkinson, S.C.; Wang, C.; Lee, A.; Bogoyevitch, M.A.; Borg, N.A.; Jans, D.A. The broad spectrum antiviral ivermectin targets the host nuclear transport importin α/β1 heterodimer. Antiviral Res., 2020, 177, 104760. doi: 10.1016/j.antiviral.2020.104760 PMID: 32135219
- Caly, L.; Druce, J.D.; Catton, M.G.; Jans, D.A.; Wagstaff, K.M. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res., 2020, 178, 104787. doi: 10.1016/j.antiviral.2020.104787 PMID: 32251768
- Lundberg, L.; Pinkham, C.; Baer, A.; Amaya, M.; Narayanan, A.; Wagstaff, K.M.; Jans, D.A.; Kehn-Hall, K. Nuclear import and export inhibitors alter capsid protein distribution in mammalian cells and reduce Venezuelan Equine Encephalitis Virus replication. Antiviral Res., 2013, 100(3), 662-672. doi: 10.1016/j.antiviral.2013.10.004 PMID: 24161512
- Guzzo, C.A.; Furtek, C.I.; Porras, A.G.; Chen, C.; Tipping, R.; Clineschmidt, C.M.; Sciberras, D.G.; Hsieh, J.Y.K.; Lasseter, K.C. Safety, tolerability, and pharmacokinetics of escalating high doses of ivermectin in healthy adult subjects. J. Clin. Pharmacol., 2002, 42(10), 1122-1133. doi: 10.1177/009127002237994 PMID: 12362927
- Muñoz, J.; Ballester, M.R.; Antonijoan, R.M.; Gich, I.; Rodríguez, M.; Colli, E.; Gold, S.; Krolewiecki, A.J. Safety and pharmacokinetic profile of fixed-dose ivermectin with an innovative 18mg tablet in healthy adult volunteers. PLoS Negl. Trop. Dis., 2018, 12(1), e0006020. doi: 10.1371/journal.pntd.0006020 PMID: 29346388
- Bryant, A.; Lawrie, T.A.; Dowswell, T.; Fordham, E.J.; Mitchell, S.; Hill, S.R.; Tham, T.C. Ivermectin for prevention and treatment of COVID-19 infection: a systematic review, meta-analysis, and trial sequential analysis to inform clinical guidelines. Am. J. Ther., 2021, 28(4), e434-e460. doi: 10.1097/MJT.0000000000001402 PMID: 34145166
- Kaur, H.; Shekhar, N.; Sharma, S.; Sarma, P.; Prakash, A.; Medhi, B. Ivermectin as a potential drug for treatment of COVID-19: An in-sync review with clinical and computational attributes. Pharmacol. Rep., 2021, 73(3), 736-749. doi: 10.1007/s43440-020-00195-y PMID: 33389725
- Altay, O.; Mohammadi, E.; Lam, S.; Turkez, H.; Boren, J.; Nielsen, J.; Uhlen, M.; Mardinoglu, A. Current status of COVID-19 therapies and drug repositioning applications. iScience, 2020, 23(7), 101303. doi: 10.1016/j.isci.2020.101303 PMID: 32622261
- Gao, K.; Nguyen, D.D.; Chen, J.; Wang, R.; Wei, G.W. Repositioning of 8565 existing drugs for COVID-19. J. Phys. Chem. Lett., 2020, 11(13), 5373-5382. doi: 10.1021/acs.jpclett.0c01579 PMID: 32543196
- Pindiprolu, S.K.S.S.; Pindiprolu, S.H. Plausible mechanisms of Niclosamide as an antiviral agent against COVID-19. Med. Hypotheses, 2020, 140, 109765. doi: 10.1016/j.mehy.2020.109765 PMID: 32361588
- Gassen, N.C.; Papies, J.; Bajaj, T.; Emanuel, J.; Dethloff, F.; Chua, R.L.; Trimpert, J.; Heinemann, N.; Niemeyer, C.; Weege, F.; Hönzke, K.; Aschman, T.; Heinz, D.E.; Weckmann, K.; Ebert, T.; Zellner, A.; Lennarz, M.; Wyler, E.; Schroeder, S.; Richter, A.; Niemeyer, D.; Hoffmann, K.; Meyer, T.F.; Heppner, F.L.; Corman, V.M.; Landthaler, M.; Hocke, A.C.; Morkel, M.; Osterrieder, N.; Conrad, C.; Eils, R.; Radbruch, H.; Giavalisco, P.; Drosten, C.; Müller, M.A. SARS-CoV-2-mediated dysregulation of metabolism and autophagy uncovers host-targeting antivirals. Nat. Commun., 2021, 12(1), 3818. doi: 10.1038/s41467-021-24007-w PMID: 34155207
- Stachulski, A.V.; Taujanskas, J.; Pate, S.L.; Rajoli, R.K.R.; Aljayyoussi, G.; Pennington, S.H.; Ward, S.A.; Hong, W.D.; Biagini, G.A.; Owen, A.; Nixon, G.L.; Leung, S.C.; ONeill, P.M. Therapeutic potential of nitazoxanide: An appropriate choice for repurposing versus SARS-CoV-2? ACS Infect. Dis., 2021, 7(6), 1317-1331. doi: 10.1021/acsinfecdis.0c00478 PMID: 33352056
- Bobrowski, T.; Chen, L.; Eastman, R.T.; Itkin, Z.; Shinn, P.; Chen, C.Z.; Guo, H.; Zheng, W.; Michael, S.; Simeonov, A.; Hall, M.D.; Zakharov, A.V.; Muratov, E.N. Synergistic and antagonistic drug combinations against SARS-CoV-2. Mol. Ther., 2021, 29(2), 873-885. doi: 10.1016/j.ymthe.2020.12.016 PMID: 33333292
- Pascoalino, B.S.; Courtemanche, G.; Cordeiro, M.T.; Gil, L.H.V.G.; Freitas-Junior, L.H. Zika antiviral chemotherapy: Identification of drugs and promising starting points for drug discovery from an FDA-approved library. F1000 Res., 2016, 5, 2523. doi: 10.12688/f1000research.9648.1 PMID: 27909576
- Tonelli, M.; Simone, M.; Tasso, B.; Novelli, F.; Boido, V.; Sparatore, F.; Paglietti, G.; Pricl, S.; Giliberti, G.; Blois, S.; Ibba, C.; Sanna, G.; Loddo, R.; La Colla, P. Antiviral activity of benzimidazole derivatives. II. Antiviral activity of 2-phenylbenzimidazole derivatives. Bioorg. Med. Chem., 2010, 18(8), 2937-2953. doi: 10.1016/j.bmc.2010.02.037 PMID: 20359898
- Law, J.N.; Akers, K.; Tasnina, N.; Santina, C.M.D.; Deutsch, S.; Kshirsagar, M.; Klein-Seetharaman, J.; Crovella, M.; Rajagopalan, P.; Kasif, S.; Murali, T.M. Interpretable network propagation with application to expanding the repertoire of human proteins that interact with SARS-CoV-2. Gigascience, 2021, 10(12), giab082. doi: 10.1093/gigascience/giab082 PMID: 34966926
- Rainsford, K.D. Influenza ("Bird Flu"), inflammation and anti-inflammatory/analgesic drugs. Inflammopharmacology, 2006, 14(1-2), 2-9. doi: 10.1007/s10787-006-0002-5 PMID: 16835706
- Srinivasan, V.; Mohamed, M.; Kato, H. Melatonin in bacterial and viral infections with focus on sepsis: A review. Recent Pat. Endocr. Metab. Immune Drug Discov., 2012, 6(1), 30-39. doi: 10.2174/187221412799015317 PMID: 22264213
- Tan, D.X.; Korkmaz, A.; Reiter, R.J.; Manchester, L.C. Ebola virus disease: Potential use of melatonin as a treatment. J. Pineal Res., 2014, 57(4), 381-384. doi: 10.1111/jpi.12186 PMID: 25262626
- Tan, D.X.; Manchester, L.C.; Terron, M.P.; Flores, L.J.; Reiter, R.J. One molecule, many derivatives: A never-ending interaction of melatonin with reactive oxygen and nitrogen species? J. Pineal Res., 2007, 42(1), 28-42. doi: 10.1111/j.1600-079X.2006.00407.x PMID: 17198536
- Galano, A.; Tan, D.X.; Reiter, R.J. On the free radical scavenging activities of melatonins metabolites, AFMK and AMK. J. Pineal Res., 2013, 54(3), 245-257. doi: 10.1111/jpi.12010 PMID: 22998574
- Xiao, J.; Shimada, M.; Liu, W.; Hu, D.; Matsumori, A. Anti-inflammatory effects of eplerenone on viral myocarditis. Eur. J. Heart Fail., 2009, 11(4), 349-353. doi: 10.1093/eurjhf/hfp023 PMID: 19213804
- Zhao, Y.; Ren, J.; Harlos, K.; Jones, D.M.; Zeltina, A.; Bowden, T.A.; Padilla-Parra, S.; Fry, E.E.; Stuart, D.I. Toremifene interacts with and destabilizes the Ebola virus glycoprotein. Nature, 2016, 535(7610), 169-172. doi: 10.1038/nature18615 PMID: 27362232
- Schwarz, S.; Wang, K.; Yu, W.; Sun, B.; Schwarz, W. Emodin inhibits current through SARS-associated coronavirus 3a protein. Antiviral Res., 2011, 90(1), 64-69. doi: 10.1016/j.antiviral.2011.02.008 PMID: 21356245
- Ho, T.; Wu, S.; Chen, J.; Li, C.; Hsiang, C. Emodin blocks the SARS coronavirus spike protein and angiotensin-converting enzyme 2 interaction. Antiviral Res., 2007, 74(2), 92-101. doi: 10.1016/j.antiviral.2006.04.014 PMID: 16730806
Supplementary files
